AbbVie Inc.
ABBV evidence brief
What we can confirm
- BioSniper Score:
- 7.6 / 10
- Market Cap:
- $439.62B
- Lead Asset:
- acuvail (Approved)
What it means
What to watch
Prepared research question
What matters most for ABBV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABBV
AbbVie Inc. (ABBV) is a global biopharmaceutical company with a diversified portfolio spanning immunology, oncology, neuroscience, and obesity, reporting total net revenues of $61.2 billion in 2025 and a Growth Platform that comprised 93% of those revenues [sec · filed 2026-03-23].
Key risk: High debt and negative equity
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 43 pipeline candidates · 337 clinical trials · 17 catalysts · 51 FDA decisions for AbbVie Inc..
AbbVie Inc. (ABBV) is a global biopharmaceutical company with a diversified portfolio spanning immunology, oncology, neuroscience, and obesity, reporting total net revenues of $61.2 billion in 2025 and a Growth Platform that comprised 93% of those revenues [sec · filed 2026-03-23].
- Total net revenues of $61.2 billion in 2025, with the Growth Platform (excluding Humira) contributing $56.6 billion, up 19.6% from 2024 [sec · filed 2026-03-23].
- Cash & equivalents of $6,569.0M, total revenue of $16,990.0M, and net income of $3,613.0M as of 2026-06-30 [sec].
- Shareholders' equity of -$5,935.0M and total debt of $62,481.0M as of 2026-06-30 [sec].
- Key assets Skyrizi and Rinvoq showed nearly 50% and 40% sales growth respectively in 2025 [sec · filed 2026-03-23].
- Experimental blood-cancer therapy etentamig achieved a 74% objective response rate in a late-stage trial for relapsed/refractory multiple myeloma, vs 45.7% for standard treatments [news · published 2026-09-04].
What works
- Strong Growth Platform performance: net revenues of $56.6 billion in 2025, up 19.6% year-over-year, with nine key assets achieving double-digit sales growth [sec · filed 2026-03-23].
- Positive late-stage data across multiple assets, including Rinvoq in alopecia areata and vitiligo, and Qulipta in migraine [sec · filed 2026-03-23].
- Robust pipeline with approximately fifteen collaborations, licensing agreements, or asset acquisitions executed, and upcoming Phase 3 starts for etentamig in AL amyloidosis and multiple myeloma [sec · filed 2026-03-23] [catalyst].
- Strategic manufacturing investments in North Carolina, Illinois, and Arizona to support immunology, neuroscience, oncology, and obesity medicines [sec_mda · as of 2026-08-03].
What to weigh
- Negative shareholders' equity of -$5,935.0M and high total debt of $62,481.0M as of 2026-06-30 [sec].
- Dependence on Growth Platform post-Humira LOE; integration risks from the Apogee acquisition, including potential delays or higher-than-expected costs [sec · filed 2026-09-03].
- Patent expiries approaching for several products, including nebivolol hydrochloride/valsartan (2027-10-04), alcaftadine (2027-12-23), and dalbavancin hydrochloride (2028-05-23) [catalyst].
- Forward-looking statements caution that risks and uncertainties may cause actual results to differ materially from expectations [sec · filed 2026-09-03].
From the filings
Quoted directly from source documents.
Growth Platform net revenues of $56.6 billion in 2025, up 19.6% from 2024
“Key asset performance drove Growth Platform net revenues of $56.6 billion, an increase of 19.6% compared to 2024.”
SEC filings · March 23, 2026
Etentamig achieved 74% objective response rate in multiple myeloma trial
“The drug produced an objective response rate of 74%, compared with 45.7% for standard treatments selected by investigators.”
News · September 4, 2026
Approximately fifteen collaborations, licensing agreements, or asset acquisitions executed
“Strengthened our pipeline with business development, including execution of approximately fifteencollaborations, licensing agreements, or other asset acquisitions.”
SEC filings · March 23, 2026
Catalyst timeline
- 2026-10-30 · Earnings — AbbVie to Host Third-Quarter 2026 Earnings Conference Call — AbbVie will announce its third-quarter 2026 financial results.
- 2026-11-02 · Phase1_Start — First-in-Human Trial of ABBV-1162 — Phase 1 double-blind, placebo-controlled trial to evaluate safety, tolerability, and pharmacokinetics of single ascending doses.
- 2026-11-29 · Phase3_Start — Etentamig in AL Amyloidosis — Phase 3 multicenter, randomized, open-label study comparing etentamig to Dara-CyBorD in newly diagnosed AL amyloidosis.
- 2026-11-30 · Phase3_Start — Etentamig in Relapsed/Refractory Multiple Myeloma — Phase 3 study evaluating etentamig plus pomalidomide vs standard therapies in 2L+ RRMM.
- 2027-01-06 · Phase3_Start — Telisotuzumab Adizutecan in NSCLC — Phase 3 open-label randomized study vs standard of care in previously treated EGFR wildtype non-squamous NSCLC.
- 2027-10-04 · Patent_Expiry — NEBIVOLOL HYDROCHLORIDE; VALSARTAN — Patent expiry for NDA206302.
- 2027-12-23 · Patent_Expiry — ALCAFTADINE — Patent expiry for NDA022134.
- 2028-05-23 · Patent_Expiry — DALBAVANCIN HYDROCHLORIDE — Patent expiry for NDA021883.
Risks & what to watch (3)›
Key risks
- High debt and negative equity — Total debt of $62,481.0M and negative shareholders' equity of -$5,935.0M as of 2026-06-30 [sec].
- Patent expiries on key products — Patent expiries for nebivolol/valsartan (2027-10-04), alcaftadine (2027-12-23), and dalbavancin (2028-05-23) [catalyst].
- Apogee acquisition integration risk — Risk that integration of Apogee's business may be more difficult, time-consuming, or costly than expected [sec · filed 2026-09-03].
What to watch
- Third-quarter 2026 earnings conference call on October 30, 2026 [catalyst].
- Phase 3 start for etentamig in AL amyloidosis (2026-11-29) and in relapsed/refractory multiple myeloma (2026-11-30) [catalyst].
- Phase 1 first-in-human trial of ABBV-1162 starting November 2, 2026 [catalyst].
- Phase 3 start for telisotuzumab adizutecan in NSCLC on January 6, 2027 [catalyst].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run AbbVie Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AbbVie Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
Net income $3.6B
Lead: Approved
43 candidates
17 upcoming, next in ~16d
0 buys · 1 sell (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 19, 2026- % of float
- 1.3%
- Days to cover
- 3.0
- Shares short
- 20,907,964
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABBV short interestGovernance
Frequently asked questions
What is the AI investment thesis for AbbVie Inc.?
AbbVie Inc. (ABBV) is a global biopharmaceutical company with a diversified portfolio spanning immunology, oncology, neuroscience, and obesity, reporting total net revenues of $61.2 billion in 2025 and a Growth Platform that comprised 93% of those revenues [sec · filed 2026-03-23].
What is AbbVie Inc.'s lead drug candidate?
AbbVie Inc.'s most advanced tracked candidate is acuvail (Approved).
What is AbbVie Inc.'s next catalyst?
AbbVie Inc.'s next tracked catalyst is a Earnings event — "Earnings: AbbVie to Host Third-Quarter 2026 Earnings Conference Call" — expected October 30, 2026.
Who is the CEO of AbbVie Inc.?
Mr. Robert A. Michael CPA is the chief executive officer of AbbVie Inc. (ABBV).
Where is AbbVie Inc. headquartered?
AbbVie Inc. (ABBV) is headquartered in North Chicago, IL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.